M.L.H. Vlaming
M.L.H. Vlaming
Director Biology, Charles River B.V., The Netherlands
Verified email at crl.com
Title
Cited by
Cited by
Year
Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice
MLH Vlaming, JS Lagas, AH Schinkel
Advanced drug delivery reviews 61 (1), 14-25, 2009
2752009
Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice
MLH Vlaming, K Mohrmann, E Wagenaar, DR de Waart, RPJO Elferink, ...
Journal of Pharmacology and Experimental Therapeutics 318 (1), 319-327, 2006
1762006
Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood–brain barrier
A Soontornmalai, MLH Vlaming, JM Fritschy
Neuroscience 138 (1), 159-169, 2006
1482006
Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo
MLH Vlaming, Z Pala, A van Esch, E Wagenaar, DR de Waart, ...
Clinical Cancer Research 15 (9), 3084-3093, 2009
1122009
Multidrug resistance proteins 2 and 3 provide alternative routes for hepatic excretion of morphine-glucuronides
K van de Wetering, N Zelcer, A Kuil, W Feddema, M Hillebrand, ...
Molecular pharmacology 72 (2), 387-394, 2007
1102007
Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics
JS Lagas, ML Vlaming, O van Tellingen, E Wagenaar, RS Jansen, ...
Clinical Cancer Research 12 (20), 6125-6132, 2006
1082006
P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide
JS Lagas, L Fan, E Wagenaar, MLH Vlaming, O van Tellingen, JH Beijnen, ...
Clinical Cancer Research 16 (1), 130-140, 2010
942010
Hepatic transport mechanisms of cholyl-L-lysyl-fluorescein
DR de Waart, S Häusler, MLH Vlaming, C Kunne, E Hänggi, HJ Gruss, ...
Journal of Pharmacology and Experimental Therapeutics 334 (1), 78-86, 2010
832010
Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo
MLH Vlaming, A van Esch, Z Pala, E Wagenaar, K van de Wetering, ...
Molecular cancer therapeutics 8 (12), 3350-3359, 2009
742009
Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate
MLH Vlaming, Z Pala, A van Esch, E Wagenaar, O van Tellingen, ...
Clinical Cancer Research 14 (24), 8152-8160, 2008
682008
Pharmacokinetic assessment of multiple ATP-binding cassette transporters: the power of combination knockout mice
JS Lagas, MLH Vlaming, AH Schinkel
Molecular interventions 9 (3), 136, 2009
652009
Predicting carrier-mediated hepatic disposition of rosuvastatin in man by scaling from individual transfected cell-lines in vitro using absolute transporter protein …
S Bosgra, E van de Steeg, ML Vlaming, KC Verhoeckx, MT Huisman, ...
European Journal of Pharmaceutical Sciences 65, 156-166, 2014
582014
Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of OATP1B1
E van de Steeg, R Greupink, M Schreurs, IHG Nooijen, KCM Verhoeckx, ...
Drug Metabolism and Disposition 41 (3), 592-601, 2013
552013
Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and …
MLH Vlaming, A van Esch, E van de Steeg, Z Pala, E Wagenaar, ...
Drug metabolism and disposition 39 (8), 1338-1344, 2011
512011
Breast cancer resistance protein (Bcrp1/Abcg2) is expressed in the harderian gland and mediates transport of conjugated protoporphyrin IX
JW Jonker, S Musters, MLH Vlaming, T Plosch, KER Gooijert, ...
American Journal of Physiology-Cell Physiology 292 (6), C2204-C2212, 2007
412007
Liquid chromatography–tandem mass spectrometric assay for sorafenib and sorafenib–glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite
RW Sparidans, MLH Vlaming, JS Lagas, AH Schinkel, JHM Schellens, ...
Journal of Chromatography B 877 (3), 269-276, 2009
392009
Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2
DR de Waart, MLH Vlaming, C Kunne, AH Schinkel, RPJO Elferink
Drug metabolism and disposition 37 (8), 1698-1702, 2009
302009
To apply microdosing or not? Recommendations to single out compounds with non-linear pharmacokinetics
S Bosgra, MLH Vlaming, WHJ Vaes
Clinical pharmacokinetics 55 (1), 1-15, 2016
232016
Bcrp1; Mdr1a/b; Mrp2 combination knockout mice: altered disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine) and its genotoxic …
MLH Vlaming, SF Teunissen, E van de Steeg, A van Esch, E Wagenaar, ...
Molecular pharmacology 85 (3), 520-530, 2014
232014
PET-CT imaging with [18F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug–drug interactions at the murine blood–brain barrier
MLH Vlaming, T Läppchen, HT Jansen, S Kivits, A van Driel, ...
Nuclear medicine and biology 42 (11), 833-841, 2015
222015
The system can't perform the operation now. Try again later.
Articles 1–20